e13504 Background: JNJ26481585 is a novel orally active pan-histone deacetylase
inhibitor (HDACI) which showed potent antitumor efficacy in a wide range of animal tumor …

Historically, numerous industries have used a variety of methods to obtain early warning
signs of potential future problems. One of the most well known of these is the canary that …

The tumor vasculature delivers nutrients, oxygen, and therapeutic agents to tumor cells.
Unfortunately, the delivery of anticancer drugs through tumor blood vessels is often …

Background The addition of cyclo-oxygenase-2 (COX-2) inhibitors and prolonged constant
infusion (PCI) of gemcitabine to treatment for advanced non-small-cell lung cancer (NSCLC) …

TO THE EDITOR: Glasmacher et al justify their metaanalysis of itraconazole by saying that
the “efficacy of antifungal prophylaxis has not been convincingly proven.” 1 They discard our …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the role of angiogenesis in non-small cell lung cancer (NSCLC). Explain the role of …

3124 Background: ZD6474 selectively targets two key pathways in tumor growth by
inhibiting VEGF receptor-2 and EGFR tyrosine kinase activity. ZD6474 is orally active and …

Tumor vasculature is a reasonable target for cancer therapy and lower more frequent doses
of traditional chemotherapeutics [low-dose metronomic (LDM) chemotherapy] has been …

Background: Derazantinib (DZB) is a fibroblast growth factor receptor inhibitor (FGFRi) with
clinical activity in FGFR2-fusion intrahepatic cholangiocarcinoma. Biochemical kinase …

7337 Background: Cyclooxigenase-2 (COX-2) is overexpressed in about 70% of NSCLC.
Selective inhibitors of COX-2 have antitumor activity by blocking angiogenesis and …